This is not a two-question form
Characterizing dual GLP-1/GIP receptor agonists demands tools that resolve receptor engagement with specificity and spatial resolution that conventional approaches cannot provide
The Emerging Problems with GLP-1 Use The University of Chicago School of Medicine calls GLP-1s effective but complex, a term that resonates with the clinical team at Oshi
Improved kidney function: Recent developments in the management of T2D have identified the use of GLP-1s to reduce the progression of kidney disease in individuals with diabetes
Athletes using these medications should work closely with sports medicine providers, consider body composition tracking beyond just weight, maintain high protein intake even with reduced appetite, prioritize resistance training, and monitor performance metrics to catch excessive muscle loss early
However, the high development cost of GLP-1 drugs can hamper the global GLP-1 receptor agonist market growth
